Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete | ||
| N/A | Nab-paclitaxel | Solid tumours | Active | |||
| Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Spasticity, Post-stroke | Do not list | Complete | ||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Evrysdi | risdiplam | Spinal muscular atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
| Zolgensma | onasemnogene abeparvovec | Spinal muscular atrophy (SMA), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 9, 2024